UNSPSC 51321814: Simfibrate

This classification denotes an anti-lipidemic agent with the molecular formula C23H26Cl2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L2R75RQX26, chemically known as 1,3-propanediol bis(alpha-(p-chlorophenoxy)isobutyrate) but generally known as simfibrate, which bears US NIH Compound Identifier 5217. European Medicines Agency schedules Simfibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10527MIG.

UNSPSC 51321814 Simfibrate (Commodity) represents pharmaceutical products being procured by state and local health agencies, fire departments, and cooperative purchasing alliances for emergency medical services, institutional pharmacy programs, and multi-state government health benefit systems. State and local buyers under this code include city fire rescue departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). The scope of procurement spans both branded and generic pharmaceutical products, with recent solicitations capturing emergency medications for Advanced Life Support protocols, direct-to-manufacturer prescription fulfillment arrangements, and bulk generic pharmaceutical and OTC product supply agreements. Vendors must meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) documentation, OSHA Hazard Communication Standards (Safety Data Sheets), and accessibility standards (WCAG 2.2 Level AA, Section 508); maintain comprehensive insurance (commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000 where required); and demonstrate supply-chain relationships with authorized drug wholesalers and capability to deliver within tight timelines (ten calendar days or less in some cases).

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 on April 24, 2026 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) with sealed-bid response due April 8, 2026 and estimated value of $40,000.00; the contract includes a Small Local Business Enterprise (SLBE) sheltered-market 5 percent bid discount capped at $10,000 and one-year initial term with two optional one-year renewals. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer pharmaceutical contracting capabilities outside traditional PBM and GPO channels, with no formal award value or timeline identified at the information-gathering phase. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with products effective July 1, 2026; pricing is weighted at 75 percent of evaluation, and vendors must pay a 3 percent administrative fee on all purchases. Contract performance extends across multiple jurisdictions including Oregon; no aggregate award value is disclosed, but vendors face performance penalties of $200 to $1,500 per violation.